The AFib-TrainNet consortium will enable promising young scientists to become excellent research leaders of the future, capable of fighting the challenges that Atrial Fibrillation (AF) presents to the European population.
AF is the most common sustained cardiac arrhythmia, occurring in between 1-2% of the general population. A very limited number of novel AF drug therapies have been introduced in the last 20 years. This imbalance reflects a gap in understanding in both how AF develops and how it can be treated, which thereby limits the development of new medicines. Our ambition with the AFib-TrainNet is to fill this gap by producing new knowledge, leading to critical insight into origins and mechanisms of sustenance of atrial fibrillation. We will accomplish this by developing novel experimental and computational models recapitulating human AF. Experimental models will be instrumental in improving the understanding AF’s underlying mechanisms, and will, along with clinical data, inform state-of-the-art computational models of human atrial electrophysiology. These new tools will permit fresh insight into the molecular, cellular and electrical mechanisms involved in the progression of healthy atria into an AF state. Our endeavor will deliver results which can be leveraged by the pharmaceutical industry to target AF drug development, and the work accomplished in AFib-TrainNet will thus constitute a beacon in the search for new AF medicine.
AFib-TrainNet is funded from the Marie Skłodowska-Curie Actions as a European Training Network (ETN).
The scientific ambition of this network is to investigate the potential of two novel drug targets for treatment of atrial fibrillation (AF). Read more
The Afib-TrainNet project has a number of partners. See the full list of partners in Organisation and Department here.